MERIDIAN BIOSCIENCE INC (VIVO) Stock Fundamental Analysis
USA - NASDAQ:VIVO - US5895841014 - Common Stock
33.97 USD
0 (0%)
33.99 USD
+0.02 (+0.06%)
We assign a fundamental rating of 6 out of 10 to VIVO. VIVO was compared to 189 industry peers in the Health Care Equipment & Supplies industry. VIVO gets an excellent profitability rating and is at the same time showing great financial health properties. VIVO has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year VIVO was profitable.
In the past year VIVO had a positive cash flow from operations.
VIVO had positive earnings in each of the past 5 years.
In the past 5 years VIVO always reported a positive cash flow from operatings.
1.2 Ratios
VIVO has a better Return On Assets (9.17%) than 88.89% of its industry peers.
VIVO has a Return On Equity of 11.54%. This is amongst the best in the industry. VIVO outperforms 87.50% of its industry peers.
With an excellent Return On Invested Capital value of 14.66%, VIVO belongs to the best of the industry, outperforming 94.44% of the companies in the same industry.
VIVO had an Average Return On Invested Capital over the past 3 years of 49.65%. This is significantly above the industry average of 9.17%.
The 3 year average ROIC (49.65%) for VIVO is well above the current ROIC(14.66%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.17% | ||
| ROE | 11.54% | ||
| ROIC | 14.66% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)49.65%
ROIC(5y)N/A
1.3 Margins
VIVO has a better Profit Margin (12.75%) than 87.04% of its industry peers.
VIVO's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 22.70%, VIVO belongs to the best of the industry, outperforming 93.52% of the companies in the same industry.
VIVO's Operating Margin has been stable in the last couple of years.
VIVO has a Gross Margin (56.56%) which is in line with its industry peers.
VIVO's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.7% | ||
| PM (TTM) | 12.75% | ||
| GM | 56.56% |
OM growth 3Y5.46%
OM growth 5Y0.35%
PM growth 3Y1.65%
PM growth 5Y3.46%
GM growth 3Y-1.43%
GM growth 5Y-1.79%
2. Health
2.1 Basic Checks
VIVO has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for VIVO has been increased compared to 1 year ago.
The debt/assets ratio for VIVO has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 11.77 indicates that VIVO is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 11.77, VIVO belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
The Debt to FCF ratio of VIVO is 0.34, which is an excellent value as it means it would take VIVO, only 0.34 years of fcf income to pay off all of its debts.
VIVO has a Debt to FCF ratio of 0.34. This is amongst the best in the industry. VIVO outperforms 93.52% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that VIVO is not too dependend on debt financing.
VIVO has a Debt to Equity ratio (0.07) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.34 | ||
| Altman-Z | 11.77 |
ROIC/WACC1.53
WACC9.57%
2.3 Liquidity
A Current Ratio of 3.63 indicates that VIVO has no problem at all paying its short term obligations.
VIVO has a Current ratio of 3.63. This is comparable to the rest of the industry: VIVO outperforms 50.00% of its industry peers.
A Quick Ratio of 2.46 indicates that VIVO has no problem at all paying its short term obligations.
VIVO has a Quick ratio (2.46) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.63 | ||
| Quick Ratio | 2.46 |
3. Growth
3.1 Past
VIVO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.86%.
Measured over the past years, VIVO shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.21% on average per year.
Looking at the last year, VIVO shows a small growth in Revenue. The Revenue has grown by 4.76% in the last year.
Measured over the past years, VIVO shows a quite strong growth in Revenue. The Revenue has been growing by 10.65% on average per year.
EPS 1Y (TTM)-17.86%
EPS 3Y26.61%
EPS 5Y15.21%
EPS Q2Q%-12.5%
Revenue 1Y (TTM)4.76%
Revenue growth 3Y18.33%
Revenue growth 5Y10.65%
Sales Q2Q%-13.82%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-39.02%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-13.66%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 24.62, the valuation of VIVO can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of VIVO indicates a rather cheap valuation: VIVO is cheaper than 83.80% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.06, VIVO is valued at the same level.
With a Price/Forward Earnings ratio of 40.37, VIVO can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, VIVO is valued a bit cheaper than the industry average as 75.93% of the companies are valued more expensively.
VIVO is valuated rather expensively when we compare the Price/Forward Earnings ratio to 32.73, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.62 | ||
| Fwd PE | 40.37 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, VIVO is valued cheaper than 86.57% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of VIVO indicates a rather cheap valuation: VIVO is cheaper than 94.44% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.27 | ||
| EV/EBITDA | 15.62 |
4.3 Compensation for Growth
VIVO has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.62
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
VIVO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
33.97
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners2.73%
Ins Owner Change0%
Market Cap1.49B
Revenue(TTM)333.02M
Net Income(TTM)42.46M
Analysts43.33
Price Target34.68 (2.09%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.65%
Min EPS beat(2)-1.96%
Max EPS beat(2)37.25%
EPS beat(4)3
Avg EPS beat(4)27.19%
Min EPS beat(4)-1.96%
Max EPS beat(4)37.25%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.54%
Min Revenue beat(2)-4.52%
Max Revenue beat(2)-0.56%
Revenue beat(4)2
Avg Revenue beat(4)6.92%
Min Revenue beat(4)-4.52%
Max Revenue beat(4)23.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.62 | ||
| Fwd PE | 40.37 | ||
| P/S | 4.49 | ||
| P/FCF | 20.27 | ||
| P/OCF | 18.15 | ||
| P/B | 4.06 | ||
| P/tB | 8.42 | ||
| EV/EBITDA | 15.62 |
EPS(TTM)1.38
EY4.06%
EPS(NY)0.84
Fwd EY2.48%
FCF(TTM)1.68
FCFY4.93%
OCF(TTM)1.87
OCFY5.51%
SpS7.57
BVpS8.36
TBVpS4.04
PEG (NY)N/A
PEG (5Y)1.62
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.17% | ||
| ROE | 11.54% | ||
| ROCE | N/A | ||
| ROIC | 14.66% | ||
| ROICexc | 18.35% | ||
| ROICexgc | 44.57% | ||
| OM | 22.7% | ||
| PM (TTM) | 12.75% | ||
| GM | 56.56% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)49.65%
ROIC(5y)N/A
ROICexc(3y)19.62%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y10.61%
ROICexgc growth 5Y2.24%
ROICexc growth 3Y13.29%
ROICexc growth 5Y-2.41%
OM growth 3Y5.46%
OM growth 5Y0.35%
PM growth 3Y1.65%
PM growth 5Y3.46%
GM growth 3Y-1.43%
GM growth 5Y-1.79%
F-Score5
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.34 | ||
| Debt/EBITDA | 0.27 | ||
| Cap/Depr | 52.18% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 173.69% | ||
| Current Ratio | 3.63 | ||
| Quick Ratio | 2.46 | ||
| Altman-Z | 11.77 |
F-Score5
WACC9.57%
ROIC/WACC1.53
Cap/Depr(3y)65.44%
Cap/Depr(5y)57.5%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)112.8%
Profit Quality(5y)119.92%
High Growth Momentum
Growth
EPS 1Y (TTM)-17.86%
EPS 3Y26.61%
EPS 5Y15.21%
EPS Q2Q%-12.5%
EPS Next Y-39.02%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.76%
Revenue growth 3Y18.33%
Revenue growth 5Y10.65%
Sales Q2Q%-13.82%
Revenue Next Year-13.66%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.75%
EBIT growth 3Y24.79%
EBIT growth 5Y11.03%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.89%
FCF growth 3Y31.57%
FCF growth 5Y14.86%
OCF growth 1Y23.18%
OCF growth 3Y31.55%
OCF growth 5Y14.77%
MERIDIAN BIOSCIENCE INC / VIVO FAQ
Can you provide the ChartMill fundamental rating for MERIDIAN BIOSCIENCE INC?
ChartMill assigns a fundamental rating of 4 / 10 to VIVO.
What is the valuation status for VIVO stock?
ChartMill assigns a valuation rating of 3 / 10 to MERIDIAN BIOSCIENCE INC (VIVO). This can be considered as Overvalued.
Can you provide the profitability details for MERIDIAN BIOSCIENCE INC?
MERIDIAN BIOSCIENCE INC (VIVO) has a profitability rating of 4 / 10.
What is the valuation of MERIDIAN BIOSCIENCE INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MERIDIAN BIOSCIENCE INC (VIVO) is 24.62 and the Price/Book (PB) ratio is 4.06.
What is the earnings growth outlook for MERIDIAN BIOSCIENCE INC?
The Earnings per Share (EPS) of MERIDIAN BIOSCIENCE INC (VIVO) is expected to decline by -39.02% in the next year.